GlassScriptPhysician profile
Wael Elsamman
NPI 1831419126
$16,772.29
in general payments reported to CMS, 2019-2025
49 companies · $19.34 in 2025
The $19.34 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,055 · 2020: $2,385 · 2021: $3,731 · 2022: $2,441 · 2023: $3,260 · 2024: $1,881 · 2025: $19.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,160.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,364.79 | 2019-2024 | Farxiga, Breztri, Lokelma |
| Novo Nordisk INC | $2,363.99 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $1,083.99 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $975.79 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $813.29 | 2019-2024 | Eliquis |
| Pfizer INC. | $792.38 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $748.42 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $684.67 | 2019-2023 | Xifaxan |
| Abbvie INC. | $647.12 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $510.92 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $433.01 | 2019-2022 | |
| Amarin Pharma, INC. | $301.28 | 2019-2022 | |
| Amgen INC. | $295.35 | 2022-2024 | Repatha, Otezla |
| Sunovion Pharmaceuticals INC. | $200.28 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $192.37 | 2019-2023 | Steglatro, Belsomra |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wael Elsamman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.